Immunome, Inc. (IMNM) vs MBX Biosciences, Inc. (MBX)

Immunome, Inc. and MBX Biosciences, Inc. are both Biotechnology companies. Immunome, Inc. and MBX Biosciences, Inc. are of similar size ($2.7B and $2.6B). Across the 9 metrics below, MBX Biosciences, Inc. leads on 7 and Immunome, Inc. on 2.

Valuation

Metric IMNM MBX Biotechnology median
P/E n/m n/m 7.88
P/S 190.93 n/m 11.47
P/B 4.58 6.25 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 149.65 n/m 10.73
Earnings yield (11.92%) (4.49%) (28.84%)
Free cash flow yield (9.11%) (3.33%) (23.03%)

Profitability

Metric IMNM MBX Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (64.03%) (33.17%) (57.72%)
Return on assets (59.03%) (31.25%) (49.22%)
Return on invested capital (3,322.99%) 0.00% 0.00%

Growth

Metric IMNM MBX Biotechnology median
Revenue growth (TTM) 16.74% — 5.64%
EPS growth (last fiscal year) 51.40% 59.11% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IMNM MBX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.08 18.08 4.73
Net debt to EBITDA 2.92 3.82 0.96

Dividend

Metric IMNM MBX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric IMNM MBX Biotechnology median
Market cap 2.56b 2.67b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack